PMCB Stock Forecast: PharmaCyte Biotech, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.98
−12.83% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$2.6M
Ticker Nerd rank
25/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$962K
Net income−$4.4M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 Apr 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−40.5%
1M
−38.9%
YTD
−71.1%
1Y
−66.8%
From 52W high
−82.9%
From 52W low
0.0%
$4
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores PharmaCyte Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
25/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
87
Quality
59
Volatility
49
Issuance
33
Revisions
20
Value
13
Growth
11
Momentum
10

Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PMCB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PMCB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26PMCB

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Nov 2021HC Wainwright & Co.InitiatesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PMCB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PMCB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, PharmaCyte Biotech, Inc. returned −66.8% against +6.9% for the S&P 500, dividends included.

PMCB vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26PMCBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PMCB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.1×

Cheaper than 96% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−44.0%

Higher than 23% of US stocks

Return on assets
−8.3%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PharmaCyte Biotech, Inc. has a market value of $2.6M.

  • Revenue in the twelve months to 30 Apr 2026: $0.0.

  • Net income over the same four quarters: −$19.4M.

  • Free cash flow in the twelve months to 30 Apr 2026: −$5.2M.

  • PharmaCyte Biotech, Inc. spent $402K on share buybacks in the twelve months to 30 Apr 2026.

  • Shares outstanding: 10.7M.

  • PharmaCyte Biotech, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

PMCB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PMCBPharmaCyte Biotech, Inc.$2.6M25
ERNAErnexa Therapeutics, Inc.$2.2M18
LABTLakewood-Amedex Biotherapeutics, Inc.$2.2M17
HCWBHCW Biologics Inc.$2.4M48
ONCOOnconetix, Inc.$2.4M16
REVBRevelation Biosciences, Inc.$2.4M14
SXTP60 Degrees Pharmaceuticals, Inc.$2.1M36

Take a look at PMCB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own PharmaCyte Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PMCB

How does Ticker Nerd's model rank PMCB?

As at 21 Nov 2026, PharmaCyte Biotech, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).

What is the PMCB stock forecast for 2030?

No analyst covering PharmaCyte Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMCB are extrapolating price history, which says nothing about the business.

How has PMCB stock performed over the past year?

PharmaCyte Biotech, Inc. returned -66.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PharmaCyte Biotech, Inc. do?

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes. Its core platform is Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology designed to support therapies for difficult-to-treat conditions, including inoperable pancreatic cancer and other solid tumors.

Company

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes. Its core platform is Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology designed to support therapies for difficult-to-treat conditions, including inoperable pancreatic cancer and other solid tumors. The company’s work centers on applying this platform to create treatment candidates that protect and deliver living cells in a controlled way. PharmaCyte Biotech is also active in related areas such as malignant ascites, reflecting a broader focus on oncology and metabolic disease applications. Headquartered in Las Vegas, Nevada, PharmaCyte Biotech operates as a research-driven company in the health technology sector, with its current business concentrated on advancing product development and commercialization efforts in specialized cellular medicine.

CEO Mr. Joshua N. Silverman · 2 employees · United States · https://pharmacyte.com